Mylan Laboratories LTD | Date: 2014-05-28
The present invention relates to an improved process for the preparation of compound of Formula-II, which is an intermediate in the preparation of HMG-CoA reductase inhibitors. wherein X is hydrogen or hydroxy protecting group and R
Mylan Laboratories Ltd | Date: 2014-05-15
The present invention relates to polymorphic forms of Febuxostat and processes for the preparation of polymorphic forms of Febuxostat.
Mylan Laboratories LTD. | Date: 2012-12-07
Apparatus for the industrial wiring and final testing of photovoltaic concentrator modules, consisting of a module frame, a lens disc, a sensor carrier disc and an electrical line routing arrangement, comprising the following features: a) a laser contact-making device for the contactless connection of connecting lines between the individual sensors and of connecting elements and of collective contact plates, wherein the line routing arrangement on the sensor carrier disc as basic structure has in each case 5 CPV sensors connected in parallel, and these parallel circuits are connected in series, b) a device for testing electrical properties, wherein a specific voltage is applied to CPV sensors themselves, and the light emitted by them via the lenses is detected and assessed, c) a device for testing tightness of finished concentrator modules, wherein compressed air is applied to the modules in the interior and the emission of compressed air is checked.
Mylan Laboratories Ltd. | Date: 2014-05-08
The present invention relates to an improved process for the preparation of Roflumilast. The present invention also relates to crystalline Form-I of Roflumilast.
Mylan Laboratories Inc. | Date: 2014-03-14
The presently disclosed subject matter is directed to a granule, wherein the granule has an active agent and a wax dispersed therein, and the granule exhibits excellent friability when compressed to form a pharmaceutical composition. The subject matter disclosed herein is also directed to methods of preparing the granules and the pharmaceutical compositions comprising the granules. The compositions and methods disclosed provide granules and pharmaceutical compositions for immediate release of the active agent and do not substantially prolong the release of the active agent from the granule.